External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)
RecruitingNCT05537662Phase: NAStarted 2023-06-06
Summary
This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pai
Eligibility
Sex
ALL
Min Age
18 Years
Max Age
None
Locations
Rush University Medical CenterChicago, Illinois, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT05537662